An observational study in Iddvt and Pulmonary Embolism (PE), sponsored by Ruijin Hospital. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Ruijin Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Pulmonary Embolism with a site in China — 26 open to participants now, 31 under way, 1 of them phase 3. Pulmonary Embolism · China.
Among the 72 studies in Pulmonary Embolism with a site in China, this one is the 22nd largest by planned enrollment of the 39 observational ones that give a count, is one of 8 that started in 2024, is one of 39 observational ones, reaches primary completion later than 14 of the 30 other live ones, and was the 59th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →26 of the 72 studies in Pulmonary Embolism with a site in China are open now. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in China
Ages 18+
Navy General Hospital, Beijing · Sites in China
Ages 18+
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18+ · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Median enrollment 417 across the 33 interventional studies, 1,000 across the 39 observational. Of the 28 that completed or were terminated, 7 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 72 have an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Ruijin Hospital has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
9 of the studies in Pulmonary Embolism with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT06596941Ruijin HospitalUltrasound Assessment of Isolated Distal Deep Vein Thrombosis | 2026-12-31 |
| NCT05482269Shengjing HospitalAdverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography | 2026-12-31 |
| NCT05098769Shengjing HospitalA Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA. | 2026-12-31 |
| NCT06341231Xiangya Hospital of Central South UniversityPersonalized Anticoagulant Therapy for Pulmonary Thromboembolism | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 72 studies in Pulmonary Embolism with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Retrospective assessment of ultrasound and clinical characteristics of patients with IDDVT, development of a pulmonary embolism risk prediction model for thrombus, and provision of appropriate diagnostic and therapeutic recommendations.
Both male and female
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of new-onset IDDVT confirmed by lower limb vascular ultrasound; presence/absence of pulmonary embolism clarified by pulmonary artery CTA; ultrasound and pulmonary artery CTA results spanning no more than 5 days.
Exclusion Criteria:
Anticoagulation therapy in the last month; pregnancy or puerperium; recurrent DVT or PE.
IDDVT with PE
IDDVT patients with concomitant PE
Time frame: At the initial visit
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.